(TheNewswire)
Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or" Voyageur ") announces that on July 10, 2023, it issued 383,360Deferred Share Units ("DSUs") to directors of the Companypursuant to its fixed 10% equity incentive compensation plan (the"Plan"). Each DSU represents a right of the holder toreceive one common share ("Common Share") of the Companyeffective as of the date that the holder ceases service as a directorof the Company. The DSUs are used to compensate directors of theCorporation for their annual retainers and are issued quarterly usinga deemed value that is equal to the weighted average share priceduring that quarter. The DSUs do not have an exercise price but have astarting value equal to approximately $.0815 per DSU, based on theweighted average share price for the quarter ended June 30, 2023. TheDSUs are subject to the terms of the Plan and the policies of the TSXVenture Exchange (the "Exchange"). The DSUs and any CommonShares issued pursuant to the exercise of the DSUs are subject to afour month hold in accordance with the policies of theExchange.
About Voyageur PharmaceuticalsLtd.
Voyageur, a Canadian public company trading under thesymbol VM on the TSXV, is in development of barium, iodine and carbonActive Pharmaceutical Ingredients (API) and high-performance,cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium, iodine and carbon contrast imagingmarket, Voyageur aims to become a key player by producing its ownbarium, iodine, and fullerene minerals.
Our business plan is set to generate cash flow bypartnering with established third-party GMP pharmaceuticalmanufacturers in Canada, ensuring the validation of our products byregulatory agencies worldwide. As we solidify our presence in themarket, we will transition into a high-margin domestic manufacturer ofradiology drugs, further expanding our revenue streams.
Voyageur is committed to sustainability andenvironmental stewardship. We envision a future where carbonneutrality is the norm, and to achieve this, we are buildingstate-of-the-art carbon-neutral infrastructure. By investing in carbonneutral energy sources and sustainable manufacturing practices, we aimto become 100% self-sufficient across all our manufacturingactivities. Our commitment to the environment sets us apart as apioneer in the industry.
At the core of our operations, Voyageur owns a 100%interest in two barium sulphate (barite) projects, including theFrances Creek and Pedley Mountain property. Additionally, Voyageurholds interests in a high-grade iodine, lithium, and bromine brineproject situated in Utah, USA, further bolstering our position in theindustry. Voyageur owns a 100% interest in two battery mineralprojects which focus on copper/zinc development.
Our ambitious vision is to become the first verticallyintegrated, carbon-neutral company in the imaging contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to the final production, we plan to ensure unmatchedquality and cost efficiency.
We embody the motto of " From the Earth to the Bottle ," highlighting our commitment to
responsible sourcing and manufacturingpractices.
For FurtherInformation: | |||
BrentWillis | AlDeslauriers | ||
President &CEO | CFO | ||
Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.
Cautionary Statement Regarding“Forward-Looking” Information
This news releasemay contain certain forward-looking information and statementsincluding statements regarding the Company's business plans. Allstatements included herein, other than statements of historical fact,are forward-looking information and such information involves variousrisks and uncertainties. There can be no assurance that suchinformation will prove to be accurate, and actual results and futureevents could differ materially from those anticipated in suchinformation. A description of assumptions used to develop suchforward-looking information and a description of risk factors that maycause actual results to differ materially from forward-lookinginformation can be found in the Company's disclosure documents on theSEDAR website at www.sedar.com. Voyageur does not undertake to updateany forward-looking information except in accordance with applicablesecurities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.